12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Belinostat regulatory update

Topotarget said the European Commission granted Orphan Drug designation for the company's belinostat to treat peripheral T cell lymphoma (PTCL). The small molecule histone deacetylase (HDAC)...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >